Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
It is well known that in the brain of the patients with Alzheimer's disease there is a
glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity
antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the
disease could provide neuroprotective effects and delay of progression. The effects of
memantine should be compared to those of donepezil, which is the most prescribed
anticholinesterase drug.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Miguel Servet
Collaborators:
Clinica Quiron de Zaragoza Hospital de Barbastro Hospital Royo Villanova Universidad de Zaragoza